Larvol Delta - A-Phase-3-Study-to-Evaluate-the-Efficacy-and-Safety-of-Efgartigimod-IV-in-Patients-With-Acetylcholine-Receptor-Binding-Antibody-Seronegative-Generalized-Myasthenia-Gravis

Vyvgart (efgartigimod alfa-fcab) - argenx, Broteio

http://clinicaltrials.gov/ct2/show/NCT06298552

Aug 11, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next